Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, Wohlrab J, Amaya-Guerra M, Kaszuba A, Nadashkevich O, Tsai TF, Gupta P, Tan H, Valdez H, Mallbris L, Tatulych S. Menter MA, et al. Among authors: krueger jg. J Drugs Dermatol. 2016 May 1;15(5):568-80. J Drugs Dermatol. 2016. PMID: 27168266 Clinical Trial.
The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR. Papp K, et al. Among authors: krueger jg. J Am Acad Dermatol. 2001 Nov;45(5):665-74. doi: 10.1067/mjd.2001.117850. J Am Acad Dermatol. 2001. PMID: 11606914 Clinical Trial.
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Papp KA, et al. Among authors: krueger jg. N Engl J Med. 2012 Mar 29;366(13):1181-9. doi: 10.1056/NEJMoa1109017. N Engl J Med. 2012. PMID: 22455412 Free article. Clinical Trial.
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.
Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, Dong H, Krueger JG, Russell CB, Martin DA. Papp KA, et al. Among authors: krueger jg. J Invest Dermatol. 2012 Oct;132(10):2466-2469. doi: 10.1038/jid.2012.163. Epub 2012 May 24. J Invest Dermatol. 2012. PMID: 22622425 Free article. Clinical Trial. No abstract available.
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG. Sofen H, et al. Among authors: krueger jg. J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025. J Allergy Clin Immunol. 2014. PMID: 24679469 Free article. Clinical Trial.
Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis.
Harden JL, Johnson-Huang LM, Chamian MF, Lee E, Pearce T, Leonardi CL, Haider A, Lowes MA, Krueger JG. Harden JL, et al. Among authors: krueger jg. J Allergy Clin Immunol. 2015 Feb;135(2):553-6. doi: 10.1016/j.jaci.2014.05.046. Epub 2014 Jul 29. J Allergy Clin Immunol. 2015. PMID: 25085340 No abstract available.
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
Papp K, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B, Zeiher B, Krueger JG. Papp K, et al. Among authors: krueger jg. Br J Dermatol. 2015 Sep;173(3):767-76. doi: 10.1111/bjd.13745. Epub 2015 Jun 19. Br J Dermatol. 2015. PMID: 25704750 Clinical Trial.
455 results